Scottish Medicines Consortium
SMC Evaluation Project
Laura McIver,
Dr Paul Catchpole,
On behalf of SMC Evaluation Management
Group
ABPI Conference, 17th November 2006
Scottish Medicines Consortium
Remit of Evaluation
• To assess the impact and effectiveness of SMC
Advice in NHS Scotland
• To inform Scottish practice around managed
introduction of new medicines
• To contribute to the wider understanding of
organisations that assess new technologies
Scottish Medicines Consortium
Project Team Links
SMC Management
group
SMC reference
group
Project team:
Bill Ramsay
NHS/Industry Marion Bennie
Groups/Networks Corri Black
Vicky Cairns
Sharon Hems
Samuel Oduro
Scottish Medicines Consortium
Industry and Organisations represented
on the Reference Group
• Martin Coombes, AstraZeneca
• Andrew McGuigan, Janssen-Cilag
• Jim Swift, Takeda
• Patient and Public Representative
• Bipolar Fellowship Scotland
• HIV Scotland
• NHS ADTCs / Chief Executive / Director of Finance
• University Academics
• Scottish Executive Health Department
Scottish Medicines Consortium
Programme Elements
SMC Evaluation Programme
Impact of SMC Evaluation of Evaluation of Supporting
decisions on SMC budget SMC’s linkage of
medicines forecasts with engagement clinical
utilisation resource with key information
across the usage within stakeholders and medicines
health care NHS Scotland utilisation data
system. over time
Scottish Medicines Consortium
Medicine Utilisation
Accepted Classification of Medicines Restricted
Unique Not Recommended Antimicrobials Cancer
Sample from
each group selected. Reviewed and verified by
clinical networks and Reference Group
Data Sources and Collection
Primary care Data (either per month or per quarter)
- Information Services Division
• volume/amount issued
Secondary Care
- Pharmacy Systems and Clinicians • total cost/expenditure for the medicine
Pharmaceutical Industry • no. of patients prescribed the medicine
Scottish Medicines Consortium
Medicine Utilisation
Data Sources and Collection
Analysis of data and draft report
Validation and Interpretation
via
Clinical Networks, ADTC Networks,
Reference Group and Industry
Issue report
Scottish Medicines Consortium
Classification of Data
Clinical Area Cancer Antimicrobials Unique / Other Total
Innovative
Recommendation type
Accepted 10 4 1 53 68
Accepted for 16 12 6 48 82
Restricted use
Not 10 5 1 41 57
recommended
Total 36 21 8 142 207
Scottish Medicines Consortium
Not Recommended Medicines
in Primary Care
£40,000
£35,000
£30,000
Restricted approval
Not Recommended by SMC
by NICE
Gross Ingredient Cost
£25,000
£20,000
£15,000
£10,000
£5,000
£0
2002/03 Q3
2002/03 Q4
2003/04 Q1
2003/04 Q2
2003/04 Q3
2003/04 Q4
2004/05 Q1
2004/05 Q2
2004/05 Q3
2004/05 Q4
2005/06 Q1
2005/06 Q2
2005/06 Q3
2005/06 Q4
Financial Year Quarter
Note: GIC obtained from Prescribing Information System for Scotland (PRISMS)
Scottish Medicines Consortium
Outputs
• Scottish patients access to individual
medicines reviewed by SMC
• Qualitative and quantitative data
• Generic key findings / learnings
• Recommendation next steps and actions
Scottish Medicines Consortium
SMC Evaluation Programme
Evaluation of
SMC’s engagement
with key
stakeholders.
Patient and Public Involvement Pharmaceutical NHS
Sub-Group (PAPIG) Industry
ADTC role and processes reviewed
Scottish Centre for Social
Key themes identified
Research
Opportunity exists to share experience
and identify examples of good practice
Scottish Medicines Consortium
Engagement with Industry
• Industry can provide the project with important
additional medicines uptake datasets:
• Secondary care
• Primary care
• To support both primary analysis (mainly
secondary care) and to cross validate and
supplement existing NHS datasets
• Evidence collection template (quantitative and
qualitative data) presently being finalised for issue
to companies
Scottish Medicines Consortium
Summary
• Work programme progressing well and to plan
• Challenges around data collection which can
partially be addressed by engagement of industry
• Validation and interpretation needs to be robust
• Contextual qualitative evidence also required to
support the quantitative information gathered
• ABPI and industry support crucial to the project